deamidation is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Free base form |
| Molecular mass | Approximately 4813 Da | Calculated from the sequence |
| Amino acid residues | 39 | GIP-derived backbone |
| Receptor targets | GIP and GLP-1 | Dual agonist |
| Circulating half-life | About 5 days | Supports weekly administration |
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
=== Age-related macular degeneration === A Cochrane review concluded that there were no changes seen for risk of developing age-related macular degeneration (AMD) from long-term vitamin E supplementation and that supplementation may slightly increase the chances of developing late AMD.
Absorption spectroscopy techniques (e.g., FTIR, ultraviolet-visible ("UV-vis") spectroscopy) measure how much light a sample absorbs at each wavelength. The most straightforward way to do this, the "dispersive spectroscopy" technique, is to shine a monochromatic light beam at a sample, measure how much of the light is absorbed, and repeat for each different wavelength. The dispersive spectroscopy technique is used by some UV–vis spectrometers to take measurements. Fourier transform spectroscopy is a less intuitive way to obtain the same information. Rather than shining a monochromatic beam of light (a beam composed of only a single wavelength) at the sample, this technique shines a beam containing many frequencies of light at once and measures how much of that beam is absorbed by the sample. Next, the beam is modified to contain a different combination of frequencies, giving a second data point. This process is rapidly repeated many times over a short time span. Afterwards, a computer takes all this data and works backward to infer what the absorption is at each wavelength. The beam described above is generated by starting with a broadband light source—one containing the full spectrum of wavelengths to be measured. The light shines into a Michelson interferometer—a certain configuration of mirrors, one of which is moved by a motor. As this mirror moves, each wavelength of light in the beam is periodically blocked, transmitted, blocked, transmitted, by the interferometer, due to wave interference.
Americium-243, an alpha emitter, has a half-life of 7350 years, the longest of all americium isotopes. It is formed in the nuclear fuel cycle mainly by neutron capture on plutonium-242 followed by beta decay. Production increases exponentially with increasing burnup as a total of 5 neutron captures on 238U are required. If MOX-fuel is used, particularly MOX-fuel high in 241Pu and 242Pu, more americium overall and more 243Am will be produced. It decays by either emitting an alpha particle (decay energy 5.439 MeV) to become 239Np, which then quickly goes to 239Pu, or, very rarely, spontaneous fission. The fission rate is about 60% that of americium-241 or about 0.7/g/s. As for the other americium isotopes, and more generally for all alpha emitters, 243Am is carcinogenic in case of internal contamination after being inhaled or ingested. 243Am also presents a risk of external irradiation associated with the gamma ray emitted by its short-lived decay product 239Np. The external irradiation risk for the other two americium isotopes (241Am and 242mAm) is less than 10% of that for americium-243.
Sources: en.wikipedia.org
==== Web-based ==== A web-based LIMS architecture is a hybrid of the thick- and thin-client architectures. While much of the client-side work is done through a web browser, the LIMS may also require the support of desktop software installed on the client device. The end result is a process that is apparent to the end-user through a web browser, but perhaps not so apparent as it runs thick-client-like processing in the background. In this case, web-based architecture has the advantage of providing more functionality through a more friendly web interface. The disadvantages of this setup are more sunk costs in system administration and reduced functionality on mobile platforms.
== Chemical structure == α-Amanitin is a highly modified bicyclic octapeptide consisting of an outer and an inner loop. The outer loop is formed by peptide bonds between a carboxyl terminus of an amino acid to the subsequent amino terminus of the next residue. The inner loop is closed by an oxidized tryptathionine linkage between 6-hydroxy-tryptophan and cysteine, which is responsible for holding the molecule in the proper conformation for binding to its protein target. In addition, α-amanitin is decorated with modified amino acid side chains (2S,3R,4R)-4,5-dihydroxy-isoleucine, trans-4-hydroxy-proline, which gives its high affinity for RNA polymerase II and III.
On the other hand, by inhibiting miR-33 function, the level of ABCA1 is increased, which increases the cholesterol efflux to apoA-1. Suppression of miR-33 will lead to less cellular cholesterol and higher plasma HDL level through the regulation of ABCA1 expression.
Sources: en.wikipedia.org
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.
A fatty diacid side chain promotes binding to albumin, which delays clearance from circulation. The half-life of roughly five days makes a weekly schedule practical.
No. It is a synthetic peptide whose backbone is based on the natural incretin hormone GIP. Non-natural residues and the lipid side chain were engineered to improve stability and duration of action.
RP-HPLC is widely used for purity and impurity profiling. Mass spectrometry confirms identity.